Fibromyalgia - InDepth

An in-depth report on the causes, diagnosis, treatment, and prevention of fibromyalgia.

I Would Like to Learn About:

Related Reports

Chronic fatigue sy...Rheumatoid arthrit...Systemic lupus ery...

References

American College of Rheumatology. Fibromyalgia. rheumatology.org/patients/fibromyalgia. Updated February 2023. Accessed October 9, 2023.

Arnold LM, Bennett RM, Crofford LJ, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611-628. PMID: 30453109 www.ncbi.nlm.nih.gov/pubmed/30453109.

Berman B, Lewith G, Witt CM, D’Adamo C. Complementary and alternative medicine. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2019:chap 58.

Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. PMID: 24737367 www.ncbi.nlm.nih.gov/pubmed/24737367.

Clauw DJ. Fibromyalgia and chronic fatigue syndrome. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 258.

Comeau D, Corey D. Rheumatology and musculoskeletal problems. In: Rakel RE, Rakel DP, eds. Textbook of Family Medicine. 9th ed. Elsevier Saunders; 2016:chap 32.

Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017;1:CD012188. PMID: 28045473 www.ncbi.nlm.nih.gov/pubmed/28045473.

Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015;(10):CD008244. PMID: 26482422 www.ncbi.nlm.nih.gov/pubmed/26482422.

Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640-648. PMID: 26975749 www.ncbi.nlm.nih.gov/pubmed/26975749.

Gmuca S, Sherry DD. Fibromyalgia: treating pain in the juvenile patient. Paediatr Drugs. 2017;19(4):325-338. PMID: 28536810 www.ncbi.nlm.nih.gov/pubmed/28536810.

Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5(2). pii: E20. PMID: 28536363 www.ncbi.nlm.nih.gov/pubmed/28536363.

McBeth J, Prescott G, Scotland G, et al. Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med. 2012;172(1):48-57. PMID: 22082706 www.ncbi.nlm.nih.gov/pubmed/22082706.

Russell IJ. Fibromyalgia syndrome and myofascial pain syndrome. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. Wall and Melzack’s Textbook of Pain. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013:chap 48.

Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694. PMID: 27428009 www.ncbi.nlm.nih.gov/pubmed/27428009.

Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;(6):CD011735. PMID: 26046493 www.ncbi.nlm.nih.gov/pubmed/26046493.

Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329. PMID: 27916278 www.ncbi.nlm.nih.gov/pubmed/27916278.

Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-610. PMID: 20461783 www.ncbi.nlm.nih.gov/pubmed/20461783.

BACK TO TOP

Review Date: 12/16/2019  

Reviewed By: Diane M. Horowitz, MD, Rheumatology and Internal Medicine, Northwell Health, Great Neck, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team. Editorial update 10/09/2023.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complied with the HONcode standard for trustworthy health information from 1995 to 2022, after which HON (Health On the Net, a not-for-profit organization that promoted transparent and reliable health information online) was discontinued.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.